Titan Spine to release new Endoskeleton TC system in first-quarter 2011

NewsGuard 100/100 Score

Titan Spine announced that it will begin full commercial release of its new Endoskeleton® TC system first quarter of 2011. The Endoskeleton® TC is an interbody fusion device for the cervical spine. The product received 510(k) clearance in July of this year and has been in limited market release since early August. The device has an acid etched titanium surface and is biomechanically designed to promote spinal fusion.

“The design and technology utilized cater to the biology of healing”

Dr. Tom Wascher, neurosurgeon at the NeuroSpine Center of Wisconsin, said, "In comparison to currently available cervical interbody products, this device has several advantages. It has a large open aperture for bone graft insertion, excellent initial fixation to the bone, and has the versatility of several different footprints including the widest available footprint on the market. The combination of these factors provides for excellent mechanical stability increasing the likelihood of a solid fusion."

This represents the third regulatory clearance for Titan Spine as the company continues to build its portfolio of bioactive spinal interbody fusion devices. "The design and technology utilized cater to the biology of healing," stated Jennifer Schneider, Sr. Research and Development Engineer. "Titan Spine is pleased to offer a device that presents unique benefits to providing treatment for patients with degenerative disc disease in the cervical spine."

Surgeons are excited to learn about the bony ingrowth benefits the Endoskeleton® TC provides especially at a time when the use of BMP and plastic devices are under scrutiny.

SOURCE Titan Spine, LLC

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Tiam1 inhibition mitigates morphine tolerance and hyperalgesia in mouse model